| 4.1 -0.17 (-3.98%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.47 | 1-year : | 6.39 |
| Resists | First : | 4.69 | Second : | 5.47 |
| Pivot price | 4.17  |
|||
| Supports | First : | 3.89 | Second : | 3.4 |
| MAs | MA(5) : | 4.27 |
MA(20) : | 4.07 |
| MA(100) : | 3.7 |
MA(250) : | 2.35 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.9 |
D(3) : | 69.1 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 5.53 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRLD ] has closed above bottom band by 41.2%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.43 | 4.43 - 4.46 |
| Low: | 4 - 4.02 | 4.02 - 4.05 |
| Close: | 4.06 - 4.1 | 4.1 - 4.14 |
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Wed, 17 Jun 2026
Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sat, 13 Jun 2026
Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Moomoo
Wed, 10 Jun 2026
Prelude Therapeutics (PRLD) director granted 38,000 stock options at $3.94 - Stock Titan
Wed, 10 Jun 2026
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Sun, 31 May 2026
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 64.3 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,550 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.94 |
| Profit Margin | 0 % |
| Operating Margin | -309.6 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -95.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -4.1 |
| PEG Ratio | 0 |
| Price to Book value | 4.31 |
| Price to Sales | 15.91 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|